Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study

[1]  D. Ye,et al.  Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.

[2]  F. Saad.  Importance of early treatment in metastatic prostate cancer: a question of life or death. , 2019, The Lancet. Oncology.

[3]  A. Protheroe,et al.  Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience , 2019, Therapeutic advances in urology.

[4]  K. Pienta,et al.  Metastatic prostate cancer remains incurable, why? , 2018, Asian journal of urology.

[5]  Question and answer on adjustment for cross-over in estimating effects in oncology trials , 2019 .

[6]  Tetsuro Ito,et al.  Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. , 2018, European journal of cancer.

[7]  J. King,et al.  Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014. , 2018, Annals of epidemiology.

[8]  I. White,et al.  What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  B. Keam,et al.  Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. , 2018, The Lancet. Oncology.

[10]  J. Carles,et al.  SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017) , 2017, Clinical and Translational Oncology.

[11]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[12]  M. Parmar,et al.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.

[13]  N. Latimer,et al.  Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer , 2016, Targeted Oncology.

[14]  Keith R Abrams,et al.  Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy , 2016, Cancer medicine.

[15]  Peng Sun,et al.  Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma , 2015, Melanoma research.

[16]  Nicholas R Latimer,et al.  Treatment switching in oncology trials and the acceptability of adjustment methods , 2015, Expert review of pharmacoeconomics & outcomes research.

[17]  Keith R Abrams,et al.  Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine. , 2015, The oncologist.

[18]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[19]  M. Climent,et al.  SEOM Clinical guidelines for the treatment of metastatic prostate cancer , 2014, Clinical and Translational Oncology.

[20]  Keith R Abrams,et al.  Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  H. Møller,et al.  Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South‐East England , 2010, BJU international.

[22]  A. Whittemore,et al.  Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. , 2003, American journal of public health.

[23]  J. Robins,et al.  Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.

[24]  J. Robins,et al.  Correcting for non-compliance in randomized trials using rank preserving structural failure time models , 1991 .